Johnson & Johnson Advances Dual-Pathway Strategy in Refractory IBD

Johnson & Johnson has reported Phase 2b results for its investigational co-antibody therapy JNJ-4804, suggesting potential clinical benefit in patients with highly refractory inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). The data, presented at Digestive Disease Week 2026, add to growing interest in combination biologic strategies for patients who fail multiple advanced therapies.¹

JNJ-4804 is designed to simultaneously inhibit interleukin-23 (IL-23) and tumor necrosis factor (TNF)-alpha, two key inflammatory drivers in IBD pathogenesis. The therapy combines mechanisms of guselkumab and golimumab into a single fixed-dose co-antibody intended to enhance immune modulation.¹

Clinical Results in Treatment-Experienced Patients

The Phase 2b DUET-UC and DUET-CD studies evaluated JNJ-4804 in patients with moderately to severely active UC and CD who had inadequate response to prior biologics or systemic therapies. Many participants had failed two or more prior treatment classes, reflecting a population with limited remaining options.¹

Across cohorts, JNJ-4804 demonstrated higher clinical remission and endoscopic response rates compared with golimumab monotherapy and numerically higher outcomes versus guselkumab alone. In CD, clinical remission reached 50.8% with JNJ-4804 versus 25.4% with golimumab and 42.5% with guselkumab, while endoscopic response rates were 38.1%, 19.8%, and 33.9%, respectively.¹

Outcomes in inflammatory bowel disease are generally reduced in later lines of biologic therapy, consistent with treatment sequencing effects and increasing disease refractoriness.²

Unmet Need in Inflammatory Bowel Disease

IBD affects millions globally and is characterized by chronic, relapsing gastrointestinal inflammation. Despite advances in biologics and small-molecule therapies, a substantial proportion of patients fail to achieve sustained remission or lose response over time.³

TNF inhibitors have been a mainstay of treatment since the late 1990s, while IL-23 inhibitors represent a newer class that has expanded therapeutic options. However, single-pathway inhibition does not fully control disease in many patients, supporting interest in more comprehensive approaches.³

Rationale for Dual-Pathway Targeting

The development of JNJ-4804 reflects a broader immunology strategy aimed at targeting multiple inflammatory pathways simultaneously. TNF drives systemic inflammation and tissue injury, while IL-23 contributes to Th17-mediated mucosal immune activation, both central to IBD pathophysiology.⁴

By combining these mechanisms, dual-pathway inhibition is designed to address complementary biological drivers of disease that may not be fully suppressed by single agents. This approach remains investigational, particularly in large-scale autoimmune disease settings.

Competitive Landscape and Industry Context

The IBD treatment landscape continues to evolve as pharmaceutical companies develop more selective biologics and targeted immune modulators. IL-23 inhibition alone has already demonstrated strong efficacy in both UC and CD, reinforcing its role as a key therapeutic axis.⁵

Johnson & Johnson maintains a significant immunology portfolio, including guselkumab and golimumab, which form the mechanistic foundation of JNJ-4804. If successful in later-stage trials, the co-antibody could represent a novel engineered combination biologic approach in gastroenterology.¹

JNJ-4804 remains investigational, and further Phase 3 evaluation will be required to confirm efficacy and safety across broader patient populations.

References

1. Investigational co-antibody therapy JNJ-4804 shows potential in refractory inflammatory bowel disease. (2026 May 5). Johnson & Johnson. https://www.jnj.com/media-center/press-releases/johnson-johnson-investigational-co-antibody-therapy-jnj-4804-shows-potential-to-raise-the-bar-for-clinical-efficacy-in-treating-refractory-inflammatory-bowel-disease
   
2. Louis, E., Litkiewicz, M., Agboton, C., & Armuzzi, A. (2024 May 8). Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long-term Crohn's disease control using real-world evidence. United European gastroenterology journal. https://doi.org/10.1002/ueg2.12563
   
3. Kaplan, G. G., & Windsor, J. W. (2020 Oct 8). The four epidemiological stages in the global evolution of inflammatory bowel disease. Nature Reviews Gastroenterology & Hepatology. https://www.nature.com/articles/s41575-020-00360-x
   
4. Neurath, M. F. (2019 Jun 24). Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nature Immunology. https://www.nature.com/articles/s41590-019-0415-0
   
5. Verstockt, B., et al. (2023). IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nature Reviews Gastroenterology & Hepatology.
   https://www.nature.com/articles/s41575-023-00768-1